International projects
Program: HORIZON
Name of the project: Integrated Services for Infectious Disease Outbreak Research
Project acronym: ISIDORe
Duration of the project: 1. 2. 2022 – 31. 7. 2025
Project website: LINK
The consortium of ISIDORe project, HORIZON Research and Innovation Action supported under the call – HORIZON-INFRA-2021-EMERGENCY-02 (Grant agreement ID 101046133), is made of the capacities of European ESFRI infrastructures and coordinated networks that assembles the largest and most diverse research and service-providing instrument to study infectious diseases in Europe, with expertise from structural biology to clinical trials.
By giving scientists access to the whole extent of its state-of-the-art facilities, cutting-edge services, advanced equipment and expertise, in an integrated way and with a common goal, it will accelerate the generation of new knowledge and intervention tools to enhance Europe’s capacity for controlling emerging and epidemic infectious diseases, starting with the COVID-19 pandemic.
Program: H2020
Name of the project: VACCELERATE – European Corona Vaccine Trial Accelerator Platform
Project acronym: VACCELERATE
Duration of the project: 28. 1. 2021 – 27. 1. 2025
Project website: LINK
VACCELERATE project, H2020 Research and Innovation action supported under the call – H2020-IBA-SC1-CORONAVIRUS-2020-4 (Grant agreement ID 101037867), is a clinical research network for the coordination and conduct of COVID-19 vaccine trials comprised of academic institutions from all over Europe. The overall objective of VACCELERATE is to connect all European stakeholders involved in vaccine development to provide a pan-European platform for clinical trial design and conduct.
VACCELERATE offers expertise, services, resources and solutions to speed up existing and upcoming development programmes as well as market authorisations for new vaccines and vaccination strategies. The network serves as a single entry-point for all stakeholders in COVID-19 vaccine development (pharma, academia, European Commission, EMA, ECDC, national health authorities and others) for phase 2 and 3 trials in Europe.
Program: H2020
Name of the project: European Virus Archive GLOBAL
Project acronym: EVA-GLOBAL
Duration of the project: 1. 1. 2020 – 30. 9. 2024
Project website: LINK
EVA-GLOBAL project, H2020 Research and Innovation action supported under the call – H2020-INFRAIA-2019-1 (Grant agreement ID 871029), gathers 38 academic institutions at the forefront of human, animal and plant research in Virology, associated with key Non-Governmental Organisations including WHO and OIE. This project is built on the strong foundations constituted by two previous EVA (2009-2014), FP7 and EVAg (2014-2019), H2020 projects. This unique advanced international community aims at becoming the most responsive network to improve the control of emerging or re-emerging virus outbreaks at the global level.
EVA-GLOBAL is conceived to be an open access entity aiming at developing synergies and complementary capabilities in such a way to offer an improved access to the researchers. Through this new ambitious project, EVA-GLOBAL will become the largest virtual virus collection for human, animal and plant viruses.
Program: HORIZON
Name of the project: Alliance4Life Bridging the Research and Innovation Gap in Life Sciences
Project acronym: A4L_BRIDGE
Duration of the project: 1. 3. 2024 – 29. 2. 2028
Project website: LINK
A4L_BRIDGE project, HORIZON Coordination and support action supported under the call – HORIZON-WIDERA-2023-ACCESS-03 – European Excellence Initiative (Grant agreement ID 101136453), builds on previous successful H2020 projects – Alliance4Life (2018-2019) and A4L_ACTIONS (2021-2024). Alliance4Life is a bottom-up initiative of twelve leading life science institutions from eleven EU-13 countries that aims at closing the divide in European health research and innovation (R&I). With the A4L_BRIDGE project, the alliance focuses on a broader implementation of the successfully piloted strategic changes toward enhanced attractiveness, competitiveness, and innovation strength, and newly also addresses excellence in higher education.
The project aims to enhance scientific collaboration by establishing a Virtual Research Centre that connects various research groups. It will lay the groundwork for initial research projects to evolve into projects for Horizon Europe. The project will also develop educational programmes catering to all career stages, including mentoring, e-learning, and international internships. Additionally, it will promote knowledge transfer and organise events for end-users of health research outcomes.
Program: HORIZON
Name of the project: Zoonoses Emergence across Degraded and Restored Forest Ecosystems
Project acronym: ZOE
Duration of the project: 1. 1. 2024 – 31. 12. 2027
Project website: LINK
ZOE project, HORIZON Research and Innovation Action supported under the call – HORIZON-CL6-2023-BIODIV-01 (Grant agreement ID 101135094), will carry out innovative research and establish collaborations across an interdisciplinary consortium with expertise in geography, geobotanics, ecology, virology, immunology, epidemiology, sociology, psychology, anthropology and science dissemination from seven EU and four American countries.
Focusing on tropical biodiversity hotspots and temperate regions impacted by deforestation and related land use changes, the project will dissect the connections between ecosystem degradation, biodiversity loss and the emergence of zoonotic diseases. The researchers will use cutting-edge technologies and community engagement to inform our understanding of these connections. Furthermore, they will propose means of mitigating the escalating risks to environmental health and human well-being.
Program: HORIZON
Name of the project: Comprehensive Cancer Infrastructures 4 Europe
Project acronym: CCI4EU
Duration of the project: 1. 5. 2023 – 30. 4. 2026
Project website: LINK
CCI4EU project, HORIZON Coordination and support action supported under the call – HORIZON-MISS-2022-CANCER-01 (Grant agreement ID 101103746), is a European initiative aiming to help Member States and Associated Countries to develop a cancer care programme with an inclusive approach tailored to each nation’s baseline status, fostering increased integration between research and care.
While comprehensive cancer centres and networks have the potential to enhance care, research and education, the developmental levels of these centres vary widely. Addressing this issue, a European initiative through a capacity-building programme aims to alleviate disparities, also in the context of other actions ongoing, such as CRANE, JANE and UNCAN. The project will maximize impact by bridging with the work of ongoing EU cancer research projects.
Program: HORIZON
Name of the project: Alzheimer’s Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe
Project acronym:ADDIT-CE
Duration of the project: 1. 1. 2023 – 31. 12. 2026
Project website: LINK
ADDIT-CE project, HORIZON Coordination and support action supported under the call – HORIZON-WIDERA-2022-ACCESS-04 – Excellence Hubs (Grant agreement ID 101087124), focuses on addressing the fragmented implementation of modern Alzheimer’s disease (AD) diagnostics in clinical practice in Czechia and Slovakia. The project will support the cooperation between academia, business, government and civil society. The partnership is expected to strengthen research and innovation in the field of AD diagnostics and introduce novel technologies into AD clinical management.
ADDIT-CE will help design a national plan for combatting dementia, and will be widely disseminated to end users and society. ADDIT-CE will join forces of the involved ecosystems to revolutionise diagnostic approaches in both countries and continue to serve society even after the project’s completion.
Program: HORIZON
Name of the project: Fostering a European Research Area for Health Research
Project acronym: ERA4Health
Duration of the project: 1. 11. 2022 – 31. 10. 2029
Project website: LINK
ERA4Health project, HORIZON COFUND action supported under the call – HORIZON-HLTH-2022-DISEASE-03 (Grant agreement ID 101095426), is a European partnership that bring together partners and funding organization from different countries with the common goal of fostering high-impact translational research for addressing public health needs.
The project will increase transnational collaborative research funding for priority areas by creating a funding body for joint programming. It will focus on tackling diseases, reducing disease burden, improving public healthcare systems, and strengthening disease prevention and health promotion. ERA4Health will support relevant medical research, improve the use of health technologies, build capacity, in particular in conducting investigator initiated clinical studies at EU scale, and implement responsible research and innovation practices.
OTHER SOLVED PROJECTS IN BMC SAS
Program | Name of the project | Project acronym | Duration of the project | Project website |
---|---|---|---|---|
HORIZON | Alliance4Life Bridging the Research and Innovation Gap in Life Sciences | A4L_BRIDGE | 1. 3. 2024 – 29. 2. 2028 | https://alliance4life.ceitec.cz/ |
HORIZON | Zoonoses Emergence across Degraded and Restored Forest Ecosystems | ZOE | 1. 1. 2024 – 31. 12. 2027 | https://www.zoe-project.eu/ |
HORIZON | COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE | CCI4EU | 1. 5. 2023 – 30. 4. 2026 | https://cci4eu.eu/ |
HORIZON | Alzheimer's Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe | ADDIT-CE | 1. 1. 2023 – 31. 12. 2026 | https://addit-ce.ceitec.cz/ |
HORIZON | Fostering a European Research Area for Health Research | ERA4Health | 1. 11. 2022 – 31. 10. 2029 | https://era4health.eu/ |
HORIZON | Enabling the next generation in search of blood cancer cures | CarrerasPathfinder | 1. 9. 2024 – 31. 8. 2029 | https://carreraspathfinders.eu/ |
HORIZON | Nanobiotechnologies for Innovative Therapeutic Approaches for Cancer | NANOBIO4CAN | 1. 11. 2023 – 31. 10. 2028 | https://nanobio4can.net/ |
COST | European Network for Sigma-1 Receptor as a Therapeutic Opportunity | SIGMA-1EUROPE | 25. 10. 2024 – 24. 10. 2028 | https://www.cost.eu/actions/CA23156/ |
COST | International networking on in vitro colon models simulating gut microbiota mediated interactions | INFOGUT | 9. 10. 2024 – 8. 10. 2028 | https://www.cost.eu/actions/CA23110/ |
HORIZON | FCAECC Fellowship programme for talented researchers in cancer | AECC Talent | 1. 9. 2023 – 31. 8. 2028 | https://aecctalent.com/ |
COST | Precision medicine in biliary tract cancer | Precision-BTC-Network | 9. 10. 2023 – 8. 10. 2027 | https://precision-btc.eu/ |
COST | Wildlife Malaria Network | WIMANET | 28. 9. 2023 – 27. 9. 2027 | https://wimanet-science.github.io/web/ |
ERANET - TRANSCAN-3 (JTC 2023) | Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer | REACH | 1. 9. 2024 – 31. 8. 2027 | https://transcan.eu/output-results/funded-projects/reach.kl |
ERANET - NEURON JTC 2023 | Reward-stress interactions as neurobiological substrate for resilience and vulnerability in mental health and depression: A translational large-scale project | RESIST-D | 1. 1. 2024 – 31. 12. 2026 | https://www.era-learn.eu/network-information/networks/neuron-cofund2/neuron-cofund2-joint-call-2023/reward-stress-interactions-as-neurobiological-substrate-for-resilience-and-vulnerability-in-mental-health-and-depression-a-translational-large-scale-project |
COST | Modelling immunotherapy response and toxicity in cancer | IMMUNO-model | 2. 11. 2022 – 1. 11. 2026 | https://www.immuno-model.eu/ |
COST | Prevention, anticipation and mitigation of tick-borne disease risk applying the DAMA protocol (PRAGMATICK) | PRAGMATICK | 16. 11. 2022 – 17. 10. 2026 | https://pragmatick-action.eu/ |
COST | Identification of biological markers for prevention and translational medicine in pancreatic cancer | TRANSPAN | 11. 10. 2022 – 10. 10. 2026 | https://transpan.eu/ |
COST | Translational control in Cancer European Network | TRANSLACORE | 4. 10. 2022 – 3. 10. 2026 | https://translacore.eu/ |
COST | Information, Coding, and Biological Function: the Dynamics of Life | DYNALIFE | 2. 10. 2023 – 18. 9. 2026 | https://www.dynalife.eu/ |
COST | European Network for Skin Engineering and Modeling | NETSKINMODELS | 15. 9. 2022 – 14. 9. 2026 | https://netskinmodels-cost.com/ |
COST | Genome Editing to Treat Humans Diseases | GenE-Humdi | 15. 9. 2022 – 14. 9. 2026 | https://www.genehumdi.eu/ |
ERANET - TRANSCAN-3 (JTC 2022) | Early detection of esophageal squamous cell carcinoma with the Cytosponge coupled with molecular biomarkers and machine learning | ANGELA | 1. 9. 2023 – 31. 8. 2026 | https://www.era-learn.eu/network-information/networks/transcan-3/2nd-transcan-3-joint-call-2022/early-detection-of-esophageal-squamous-cell-carcinoma-with-the-cytosponge-coupled-with-molecular-biomarkers-and-machine-learning |
COST | A sound proteome for a sound body: targeting proteolysis for proteome remodeling | ProteoCure | 1. 11. 2023 – 6. 10. 2025 | https://proteocure.eu/ |
ERA-NET | Resistance under treatment in breast cancer | RESCUER | 1. 8. 2020 – 31. 5. 2024 | LINK |
H2020 | Alliance for Life Sciences: From Strategies to Actions in Central and Eastern Europe | A4L_ACTIONS | 1. 5. 2021 – 30. 4. 2024 | https://alliance4life.ceitec.cz/ |
COST | Determinants of Physical Activities in Settings | DE-PASS | 22. 7. 2020 – 21. 4. 2024 | LINK |
EEA and Norway Grants Fund for Regional Cooperation | TBFVnet: surveillance and research on tick-borne flaviviruses | TBFV | 1. 7. 2020 – 31. 1. 2024 | https://www.tbfvnet.eu/ |
ERA-NET | TEmprature-responsive Nanogels for TArgeted delivery of miCroRNAs in wound heaLing and tissue rEgeneration applicationS | TENTACLES | 1. 2. 2020 – 31. 1. 2024 | LINK |
ERA-NET | UNveiling the MEchanism(s) underlying the switch to mania during antidepressant treatment: The role of glutamate | UNMET | 1. 7. 2019 – 31. 1. 2024 | LINK |
HORIZON | A Coordination and Support Action to prepare UNCAN.eu platform | 4.UNCAN.eu | 1. 9. 2022 – 30. 11. 2023 | https://uncan.eu/ |
H2020 | Tick-Virus Interactions Shape persistence and Transmission OF Flavivirus pathogen in tick vector | TVISTOFF | 1. 9. 2021 – 31. 8. 2023 | https://cordis.europa.eu/project/id/101030179 |
IAEA | Molecular Markers for Biological Dosimetry in Radiation Oncology, Cancer Risk, Assesment and Optimizing Cancer Therapy | 19. 9. 2017 – 9. 7. 2023 | LINK | |
H2020 | Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers | VISION | 1. 10. 2019 – 30. 6. 2023 | https://www.sav.sk/ |
ERA-NET | Metabolic therapy of heart failure: which role for B vitamins | HF-MetaB | 1. 4. 2020 – 31. 3. 2024 | LINK |
ERA-NET | Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors | NExT | 1. 9. 2019 – 31. 3. 2023 | LINK |
COST | Aedes Invasive Mosquitoes | AIM | 29. 1. 2020 – 5. 3. 2023 | LINK |
COST | Cancer Nanomedicine – from the bench to the bedside | NANO2CLINIC | 28. 9. 2018 – 27. 3. 2023 | LINK |
COST | New diagnostic and therapeutic tools against multidrug resistant tumors | STRATAGEM | 11. 9. 2018 – 10. 9. 2022 | LINK |
3rd Health Programme | Innovative Partnership for Action Against Cancer – iPAAC | iPAAC | 1. 4. 2018 – 31. 12. 2021 | LINK |
COST | In vitro 3-D total cell guidance and fitness | CellFit | 16. 3. 2017 – 15. 9. 2021 | LINK |
ERA-NET | Innovative Nanopharmaceuticals: Targeting Breast Cancer Stem Cells by a Novel Combination of Epigenetic and Anticancer Drugs with Gene Therapy | INNOCENT | 1. 1. 2017 – 30. 6. 2021 | LINK |
COST | Drosophila salivary gland secretory proteins as tunable and biodegradable natural glue | ENBA | 1. 1. 2017 – 20. 4. 2021 | LINK |
COST | Mitochondrial mapping: Evolution - Age - Gender - Lifestyle - Environment | MITO-EAGLE | 1. 1. 2017 – 28. 2. 2021 | LINK |
COST | The Comet assay as a human biomonitoring tool | hCOMET | 1. 4. 2016 – 11. 10. 2020 | LINK |
ERA-NET | Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy | intraMMclo | 1. 7. 2016 – 31. 7. 2020 | LINK |
H2020 | European virus archive goes global | EVAg | 1. 4. 2015 – 31. 7. 2020 | LINK |
H2020 | Life Science Alliance: Closing Research and Innovation Divide in the EU | Alliance4Life | 1. 1. 2018 – 31. 12. 2019 | LINK |
H2020 | High level Integrated Sensor for Nano Toxicity Screening | HISENTS | 1. 4. 2016 – 31. 3. 2019 | LINK |
COST | Application of next generation sequencing for the study and diagnosis of plant viral diseases in agriculture | FA1407 | 9. 3. 2015 – 8. 3. 2019 | LINK |
FP7 | Clinical Development of Nitisinone for Alkaptonuria | DevelopAKUre | 1. 11. 2012 – 31. 1. 2019 | LINK |
FP7 | Anti-tick Vaccines to Prevent Tick-borne Diseases in Europe | ANTIDotE | 1. 12. 2013 – 30. 11. 2018 | LINK |
ERA-NET | MEchanisms of Lymphocytes TRansmigration Across the Blood Brain Barrier | MELTRA – BBB | 1. 8. 2015 – 31. 7. 2018 | LINKA |
ERA-NET | Development of galectin-based therapeutics for the treatment of hantaviral hemorrhagic fever | Galhant | 1. 1. 2016 – 31. 12. 2017 | LINK |
COST | Aldosterone and Mineralocorticoid Receptor | ADMIRE | 23. 11. 2016 – 30. 11. 2017 | LINK |
H2020 | Building-up Centre of Excellence for advanced materials application | CEMEA | 1. 6. 2015 – 31. 5. 2016 | LINK |
COST | Sustainable production of high-quality cherries for the European market | FA1104 | 15. 4. 2013 – 15. 4. 2016 |